Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did. Read how
Close

Citi Pharma Ltd (CITI)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
32.50 -0.03    -0.09%
03:35:45 - Delayed Data. Currency in PKR ( Disclaimer )
Type:  Equity
Market:  Pakistan
ISIN:  PK0126201018 
S/N:  CPHL
  • Volume: 1,312,701
  • Bid/Ask: 32.50 / 32.64
  • Day's Range: 32.32 - 33.18
Citi Pharma 32.50 -0.03 -0.09%

PSX:CITI Financials

 
A brief overview of the PSX:CITI financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Citi Pharma Ltd over time.

Citi Pharma Limited reported earnings results for the full year ended June 30, 2023. For the full year, the company reported sales was PKR 12,396.98 million compared to PKR 9,779.88 million a year ago. Net income was PKR 657.98 million compared to PKR 653.69 million a year ago. Basic earnings per share from continuing operations was PKR 2.88 compared to PKR 2.88 a year ago. Diluted earnings per share from continuing operations was PKR 2.88 compared to PKR 2.88 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

CITI Income Statement

Gross margin TTM 12.08%
Operating margin TTM 9.42%
Net Profit margin TTM 5.31%
Return on Investment TTM 12.33%
 Total Revenue  Net Income
Period Ending: Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022
Total Revenue 3537.38 2688.73 3052.8 3118.07
Gross Profit 231.68 350.42 545.04 370.39
Operating Income 135.77 288.35 460.35 283.01
Net Income 124.58 92.77 294.83 145.81

CITI Balance Sheet

Quick Ratio MRQ 0.78
Current Ratio MRQ 1.48
LT Debt to Equity MRQ 0.16%
Total Debt to Equity MRQ 34.29%
 Total Assets  Total Liabilities
Period Ending: Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022
Total Assets 9984.16 9993.15 8840.06 8397.01
Total Liabilities 4611.09 4773.88 3713.56 3565.33
Total Equity 5373.07 5219.27 5126.51 4831.68

CITI Cash Flow Statement

Cash Flow/Share TTM -1.44
Revenue/Share TTM 54.26
Operating Cash Flow  -16.25%
 Cash  Net Change in Cash
Period Ending: Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -723.46 -330.22 66.51 658.17
Cash From Investing Activities -713.48 30.41 -133.56 35.8
Cash From Financing Activities 756.63 581.83 79 -554.22
Net Change in Cash -680.32 282.02 11.95 139.76
* In Millions of PKR (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

CITI Comments

Write your thoughts about Citi Pharma Ltd
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Faheem Sultan
Faheem Sultan Feb 18, 2022 9:45AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
good investment for long term
Reply
3 1
Report
Rai Ahmad
Rai Ahmad Feb 18, 2022 9:45AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
abhi tk same decision chal rha h ya phr reverse
Reply
1 0
Report
Omar Khan
Omar Khan Dec 29, 2021 6:41AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
What is the future of Citi Pharma? Any potential in this share?
Reply
3 1
Report
muhammad ali khan
muhammad ali khan Dec 29, 2021 6:41AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Lelo hopefully it will go best
Reply
0 1
Report
JD Ahmed
JD Ahmed Nov 16, 2021 9:01AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Es ka divident kab credit huga ...book clouser ko 20 days guzar gye hain
Reply
4 0
Report
احمر ملک
احمر ملک Nov 16, 2021 9:01AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
credit ho gaya mera to
Reply
0 0
Report
Khalid Khan
Khalid Khan Nov 15, 2021 5:47AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
when is the dividend expected?
Reply
1 0
Report
Muhammad Ali
Muhammad Ali Oct 22, 2021 3:07PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Any expectation from Cphl 'quarterly closing' board meeting 29-10-2021
Reply
0 1
Report
Yasir siddiqui
Yasir siddiqui Oct 21, 2021 2:36AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
shall we buy cphl here or wait for more dip
Reply
0 0
Report
GlitchIn The Matrix
GlitchIn The Matrix Oct 21, 2021 2:36AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Below 35 = a good buy!
Reply
2 0
Report
Jawad Hussain
Jawad Hussain Oct 21, 2021 2:36AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
don't wait
Reply
0 0
Report
Muhammad Ismail
Muhammad Ismail Oct 12, 2021 5:35AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Abe bay karny ja time hai ise
Reply
1 0
Report
GlitchIn The Matrix
GlitchIn The Matrix Oct 12, 2021 5:35AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
yes!
Reply
0 0
Report
irfan ghaffar
IGMEMON Sep 30, 2021 4:35PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Citi Pharma Ltd. (CPHL) - AnnualBasicEPS 2021 = 4.64 PKREPS 2020 = 31.87 PKRDilutedEPS 2021 = 2.36 PKREPS 2020 = 31.87 PKRCash Dividend = 1.5 PKRBonus Share = 10%Book Closure21-10-21 To 28-10-21
Reply
3 0
Report
احمر ملک
احمر ملک Sep 30, 2021 4:35PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
divident kb mily ga??
Reply
0 0
Report
GlitchIn The Matrix
GlitchIn The Matrix Sep 30, 2021 4:35PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
احمر ملک 1st Dec
Reply
0 0
Report
احمر ملک
احمر ملک Sep 30, 2021 4:35PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
GlitchIn The Matrix ok
Reply
0 1
Report
Ali saleem kolsawala
Ali saleem kolsawala Sep 14, 2021 12:46AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Thank You for giving me thunbs down....... Milega aaur neechay milega.
Reply
1 2
Report
GlitchIn The Matrix
GlitchIn The Matrix Sep 14, 2021 12:46AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
yes below 35
Reply
0 0
Report
Ali saleem kolsawala
Ali saleem kolsawala Sep 13, 2021 7:10AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
47 ke neechany bhi milega..... wait audience..........
Reply
1 1
Report
Ali saleem kolsawala
Ali saleem kolsawala Sep 13, 2021 7:10AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Check citi today....
Reply
1 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email